Search Our Scientific Publications & Authors

Curr Treat Options Gastroenterol 2021 Mar 30;19(1):153-168. Epub 2021 Jan 30.

Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Purpose Of Review: To provide an update on latest advances in treatment of cholangiocarcinoma.

Recent Findings: Incidence of cholangiocarcinoma has been increasing over the past decade. A better understanding of the genetic landscape of cholangiocarcinoma and its risk factors resulted in earlier diagnosis and treatment option expansion to targeted therapy with FGFR inhibitors, and liver transplantation for early perihilar cholangiocarcinoma and early intrahepatic cholangiocarcinoma. Read More

Acta Neuropathol Commun 2021 04 14;9(1):69. Epub 2021 Apr 14.

Department of Neurosurgery, Rutgers-Robert Wood Johnson Medical School & University Hospital, Rutgers-New Jersey Medical School, New Brunswick, NJ, 08901, USA.

Prognostic molecular subgrouping of glioblastoma is an ongoing effort and the current classification includes IDH-wild-type and IDH-mutant entities, the latter showing significantly better prognosis. We performed a comparative integrated analysis of the FGFR glioblastoma subgroup consisting of 5 cases from a prospective 101-patient-cohort. FGFR alterations included FGFR2-TACC2 and FGFR2 amplifications arising in a multifocal IDH-mutant glioblastoma with unexpected 2. Read More

Invest New Drugs 2021 Apr 7. Epub 2021 Apr 7.

Key Laboratory of Marine Drugs, School of Medicine and Pharmacy, Chinese Ministry of Education, Ocean University of China, Qingdao, 266100, People's Republic of China.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have led to great advances in the treatment of non-small cell lung cancer (NSCLC), but the emergence of drug resistance severely limits their clinical use. Thus, elucidation of the mechanism underlying resistance to EGFR-TKIs is of great importance. In our study, sustained activation of STAT3 was confirmed to be involved in resistance to EGFR-TKIs, and this resistance occurred regardless of exposure time, EGFR-TKIs type, and even cancer cell type. Read More

Curr Opin Oncol 2021 May;33(3):221-230

Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas.

Purpose Of Review: Bladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC). Read More

Cancers (Basel) 2021 Mar 17;13(6). Epub 2021 Mar 17.

Department of Gastroenterology, Institute of Liver and Gastrointestinal Diseases, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, ranking third in cancer deaths worldwide. Over the last decade, several studies have emphasized the development of tyrosine kinase inhibitors (TKIs) to target the aberrant pathways in HCC. However, the outcomes are far from satisfactory due to the increasing resistance and adverse effects. Read More